ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma

Huang, Weimei; Lin, Anqi; Luo, Peng; Liu, Yuchen; Xu, Wentao; Zhu, Weiliang; Wei, Ting; Lyu, Qingwen*; Guo, Linlang*; Zhang, Jian*南方医科大学
Cancer Gene Therapy2021-8DOI: 10.1038/s41417-020-0207-6
26被引5阅读
引用收藏
分享

摘要

Immune checkpoint inhibitor (ICI) therapy has shown remarkable clinical benefit in lung adenocarcinoma (LUAD) patients. Genomic mutations may be applicable to predict the response to ICIs. Eph receptor A5 (EPHA5) is frequently mutated in breast cancer, lung cancer, and other tumors; however, its association with outcome in patients who receive immunotherapy remains unknown. In this study, we report that EPHA5 mutations were associated with increased tumor mutation burden (TMB), neoantigen load, levels of immune-related gene expression signatures, and enhanced tumor-infiltrating lymphocytes (TILs) in LUAD. LUAD patients with EPHA5 mutations in the immunotherapy cohort achieved a longer progression-free survival (PFS) time than patients with wild-type EPHA5. Immune response pathways were among the top enriched pathways in samples with EPHA5 mutations. In addition, patients with EPHA5 mutations tended to be more sensitive to certain targeted molecular inhibitors, including serdemetan, lox2, and PF1-1. Collectively, our results suggest that identifying mutations in the EPHA5 gene may provide insight into the genome-wide mutational burden and may serve as a biomarker to predict the immune response of patients with LUAD.

学科与关键词

关键词
STIMULATES MIGRATIONPOOR-PROGNOSISEXPRESSIONRECEPTORCELLSSTAGEIDENTIFICATIONIMMUNOTHERAPYPEMBROLIZUMABCHEMOTHERAPY
相关
加载中…
  • Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
    Wen, Yang; Lin, Anqi; Zhu, Weiliang; Wei, Ting; Luo, Peng*; Guo, Linlang*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 645862.被引 4
  • ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Zhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
  • B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
    Lin, Anqi; Fang, Jianbo; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*Journal of Inflammation Research, 2022, 15.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Gene Therapy
发表日期
2021-08
卷期
第 28 卷, 第 7-8 期
页码
864-874
DOI
10.1038/s41417-020-0207-6
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE

作者

  • H

    Huang, Weimei (第一作者)

    southern med univ

  • L

    Lin, Anqi

    southern med univ

查看全部 10 位作者收起作者
  • L

    Luo, Peng

    southern med univ

  • L

    Liu, Yuchen

    southern med univ

  • X

    Xu, Wentao

    southern med univ

  • Z

    Zhu, Weiliang

    southern med univ

  • W

    Wei, Ting

    southern med univ

  • L

    Lyu, Qingwen (通讯)

    southern med univ

  • G

    Guo, Linlang (通讯)

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417